Lundbeck and Merck sign Sycrest agreement
H. Lundbeck and Merck & Co have signed a commercialisation agreement for Sycrest (asenapine) sublingual tablets (5mg, 10mg).
H. Lundbeck and Merck & Co have signed a commercialisation agreement for Sycrest (asenapine) sublingual tablets (5mg, 10mg). The drug is used to treat moderate to severe manic episodes associated with bipolar 1 disorder in adults.
Under the terms of the agreement, Lundbeck of Denmark will pay an undisclosed fee as well as product supply payments to Merck in exchange for exclusive commercial rights to Sycrest in all markets outside the US, China and Japan.
Lundbeck says it expects to launch the product in the European Union (EU), where it is already approved, at the beginning of 2011. Merck will retain exclusive commercial rights to asenapine in the US, China and Japan. In the US, Merck has launched asenapine under the brand name Saphris.
‘This agreement highlights our strategic focus on late-stage specialist central nervous system (CNS) products and our ambition to provide long-term growth opportunities for Lundbeck,’ said Ulf Wiinberg, president and ceo at L
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance